News

DeepMind further claimed that its AI-driven system, AlphaFold, is capable of generating 3D models of proteins that are highly accurate and potentially capable of solving one of the

Momenta had previously guided that it planned to file a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this

The companies have entered into a collaboration and license agreement for TR009 (formerly known as ABL001 or NOV1501), an ABL developed bispecific antibody candidate targeting two important angiogenic

Zolgensma was previously granted breakthrough therapy designation by the US regulator. Novartis expects a regulatory action to be taken on the gene replacement therapy in May 2019. According

Based in Waltham of Massachusetts, Tesaro is a commercial-stage firm engaged in the development of advanced therapies to treat cancer. As per the terms of the deal, GSK’s

GSK’s consumer healthcare portfolio has long been regarded as high quality, safe and effective, maintaining a quality image and loyal base of consumers. OTC medications allow practitioners and

RXC006 is being developed as an orally administered and first-in-class treatment for the orphan disease idiopathic pulmonary fibrosis (IPF), which is a chronic lung condition. RXC006, which is

The Series C financing round was led by the Redmile Group, with participation by new investor Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral

The partnership is for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab). The agreement showcases the